Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GBIONASDAQ:GNPXNASDAQ:OKURNASDAQ:SRZN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGBIOGeneration Bio$0.38+1.5%$0.42$0.32▼$3.82$25.56M2.76303,148 shs353,127 shsGNPXGenprex$0.25+4.4%$0.29$0.22▼$4.09$5.97M-0.43.82 million shs1.53 million shsOKUROnKure Therapeutics$2.00-2.9%$3.29$1.70▼$20.00$26.87M0.4104,983 shs450,796 shsSRZNSurrozen$7.10+3.6%$10.09$5.90▼$18.17$23.30M0.6921,036 shs50,016 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGBIOGeneration Bio0.00%+8.63%-2.23%-43.93%-89.94%GNPXGenprex0.00%-13.35%+3.00%-43.93%-89.87%OKUROnKure Therapeutics0.00%+4.71%-30.80%-65.16%+199,999,900.00%SRZNSurrozen0.00%-14.97%-27.18%-39.37%-30.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGBIOGeneration Bio3.3859 of 5 stars3.55.00.00.00.83.31.3GNPXGenprex1.839 of 5 stars0.02.00.04.73.90.01.3OKUROnKure Therapeutics3.2115 of 5 stars3.70.00.00.03.22.51.3SRZNSurrozen3.5674 of 5 stars3.55.00.00.01.05.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGBIOGeneration Bio 3.00Buy$7.331,823.25% UpsideGNPXGenprex 0.00N/AN/AN/AOKUROnKure Therapeutics 3.33Buy$32.331,516.67% UpsideSRZNSurrozen 3.00Buy$38.50442.25% UpsideCurrent Analyst Ratings BreakdownLatest GNPX, SRZN, OKUR, and GBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025SRZNSurrozenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.005/8/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/30/2025OKUROnKure TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/10/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/2/2025SRZNSurrozenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.003/18/2025OKUROnKure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.003/17/2025GBIOGeneration BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.003/14/2025GBIOGeneration BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.003/14/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/11/2025OKUROnKure TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$35.00 ➝ $30.00(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGBIOGeneration Bio$24.56M1.04N/AN/A$3.07 per share0.12GNPXGenprexN/AN/AN/AN/A$4.99 per shareN/AOKUROnKure TherapeuticsN/AN/AN/AN/A$26.60 per shareN/ASRZNSurrozen$10.66M2.19N/AN/A$18.39 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGBIOGeneration Bio-$126.61M-$1.08N/AN/AN/A-782.86%-104.85%-49.54%N/AGNPXGenprex-$30.86MN/A0.00N/AN/AN/A-409.48%-269.17%5/21/2025 (Estimated)OKUROnKure Therapeutics-$77.39M-$5.26N/AN/AN/AN/A-51.17%-47.11%N/ASRZNSurrozen-$43.04M-$24.96N/AN/AN/AN/A-120.51%-54.68%N/ALatest GNPX, SRZN, OKUR, and GBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025N/AGNPXGenprex-$0.82N/AN/AN/AN/AN/A5/12/2025Q1 2025GNPXGenprex-$0.82-$0.26+$0.56-$0.26N/AN/A5/9/2025Q1 2025SRZNSurrozen-$1.09-$3.13-$2.04-$7.43N/A$0.98 million5/7/2025Q1 2025GBIOGeneration Bio-$0.25-$0.22+$0.03-$0.22$1.70 million$8.72 million5/6/2025Q1 2025OKUROnKure Therapeutics-$1.41-$1.19+$0.22-$1.19N/AN/A3/31/2025Q4 2024SRZNSurrozen-$2.54-$9.10-$6.56-$9.10N/A$0.66 million3/19/2025Q4 2024GBIOGeneration Bio-$0.31-$0.32-$0.01-$0.32$2.92 million$4.19 million3/10/2025Q4 2024OKUROnKure Therapeutics-$0.86-$1.37-$0.51-$1.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGBIOGeneration BioN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ASRZNSurrozenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGBIOGeneration BioN/A6.346.34GNPXGenprexN/A0.860.86OKUROnKure TherapeuticsN/A23.7123.71SRZNSurrozenN/A7.407.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGBIOGeneration Bio95.22%GNPXGenprex14.05%OKUROnKure Therapeutics90.98%SRZNSurrozen66.57%Insider OwnershipCompanyInsider OwnershipGBIOGeneration Bio21.80%GNPXGenprex8.47%OKUROnKure Therapeutics2.30%SRZNSurrozen45.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGBIOGeneration Bio15067.04 million52.70 millionOptionableGNPXGenprex2024.15 million7.79 millionNo DataOKUROnKure TherapeuticsN/A13.44 million2.75 millionN/ASRZNSurrozen803.28 million1.84 millionNot OptionableGNPX, SRZN, OKUR, and GBIO HeadlinesRecent News About These CompaniesResearch Analysts Set Expectations for Surrozen Q2 EarningsMay 17 at 2:25 AM | americanbankingnews.comDown -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a TurnaroundMay 16 at 10:35 AM | zacks.comSurrozen secures patent for tissue repair technologyMay 15 at 11:52 PM | investing.comSurrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt PathwayMay 14, 2025 | globenewswire.comSurrozen's (SRZN) Buy Rating Reaffirmed at HC WainwrightMay 13, 2025 | americanbankingnews.comSurrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 10, 2025 | finanznachrichten.deSurrozen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | globenewswire.comSurrozen files to sell 5.21M shares of common stock for holdersApril 25, 2025 | markets.businessinsider.comSurrozen reports FY24 EPS ($21.67) vs. ($21.33) last yearApril 2, 2025 | markets.businessinsider.comInsiders Are Loving These 5 Tech and Biotech StocksApril 2, 2025 | 247wallst.comSurrozen Focuses on Ophthalmology Amid Financial ChallengesApril 2, 2025 | tipranks.comSurrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesMarch 31, 2025 | globenewswire.comSurrozen, Inc. (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 1,034,482 SharesMarch 29, 2025 | insidertrades.comSurrozen to focus Wnt expertise, technologies on ophthalmology programsMarch 27, 2025 | markets.businessinsider.comSurrozen to discontinue development of SZN-043 in alcohol associated hepatitisMarch 26, 2025 | markets.businessinsider.comSurrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 DevelopmentMarch 24, 2025 | quiverquant.comSurrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye DiseasesMarch 24, 2025 | globenewswire.comSurrozen (NASDAQ:SRZN) Stock Quotes, Forecast and News SummaryJanuary 30, 2025 | benzinga.comHC Wainwright & Co. Initiates Coverage of Surrozen (SRZN) with Buy RecommendationJanuary 30, 2025 | msn.comH.C. Wainwright sets $32 target on Surrozen stock with Buy ratingJanuary 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNPX, SRZN, OKUR, and GBIO Company DescriptionsGeneration Bio NASDAQ:GBIO$0.38 +0.01 (+1.52%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.38 -0.01 (-1.39%) As of 05/16/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Genprex NASDAQ:GNPX$0.25 +0.01 (+4.39%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.25 +0.01 (+2.35%) As of 05/16/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.OnKure Therapeutics NASDAQ:OKUR$2.00 -0.06 (-2.91%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$2.02 +0.02 (+1.00%) As of 05/16/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.Surrozen NASDAQ:SRZN$7.10 +0.25 (+3.65%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$7.14 +0.04 (+0.49%) As of 05/16/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
